The similarity of selected statins - a comparative analysis

• Autorzy: Dreyer C. , Placha W. , Zgajewski J. , Dygut J. , Stangel-Wójcikiewicz K. , Piwowar M.

Identyfikatory

DOI

10.1515/bams-2018-0034

• Języki publikacji: EN

Abstrakty

EN

The paper presents the physicochemical and structural characteristics as well as the comparison of selected statins. Statins are relatively popular compounds used in modern medicine. They are increasingly often combined with other medications to improve the effectiveness of therapy. We analyzed the characteristics of pravastatin, simvastatin, atorvastatin, pitavastatin, lovastatin, mevastatin, fluvastatin, and rosuvastatin obtained from the PubChem Substance database. On the basis of data related to chemical structure and physicochemical properties, the statins were grouped into more and less similar ones. Statins are not homogeneous in terms of physicochemical properties and structure. Three groups of statins were identified. Mevastatin, lovastatin, and simvastatin are the most similar to each other, while pravastatin shows a slightly lower similarity to them. Pitavastatin and fluvastatin are also highly similar, while atorvastatin and rosuvastatin, because of their properties, are the most different from other statin groups.

Słowa kluczowe

EN

statins; comparative analysis; physicochemical characteristics

• Wydawca: Uniwersytet Jagielloński - Collegium Medicum ; Index Copernicus Sp. z o.o.
• Czasopismo: Bio-Algorithms and Med-Systems
• Rocznik: 2018
• Tom: Vol. 14, no. 4
• Strony: art. no. 20180034
• Opis fizyczny: Bibliogr. 16 poz., rys., tab.

Twórcy

autor

Dreyer C.

• Jagiellonian University - Medical College, Św. Anny 12, 31-008 Krakow, Poland

autor

Placha W.

• Jagiellonian University - Medical College, Chair of Medical Biochemistry, Kopernika 7, 31-034 Krakow, Poland

autor

Zgajewski J.

• Jagiellonian University - Medical College, Chair of Medical Biochemistry, Kopernika 7, 31-034 Krakow, Poland

autor

Dygut J.

• Jagiellonian University - Medical College, Department of Bioinformatics and Telemedicine, Łazarza 16, 31-530 Krakow, Poland

autor

Stangel-Wójcikiewicz K.

• Jagiellonian University - Medical College, Gynecology and Oncology, Kopernika 23, 31-501 Krakow, Poland

autor

Piwowar M.

• Jagiellonian University - Medical College, Department of Bioinformatics and Telemedicine, Łazarza 16, 31-530 Krakow, Poland

Bibliografia

• [1] Bizukojæ M, Ledakowicz S. Biosynteza lowastatyny przez Aspergillus terreus. Biotechnologia Monografie 2005;2:55-67.
• [2] Sirtori CR. The pharmacology of statins. Pharmacol Res 2014;88:3-11.
• [3] Bełtowski J, Wójcicka G, Jamroz-Wiśniewska A. Adverse effects of statins - mechanisms and consequences. Curr Drug Saf 2009;4:209-28.
• [4] Awad K, Banach M. The optimal time of day for statin administration: a review of current evidence. Curr Opin Lipidol 2018;29:340-5.
• [5] Awad K, Serban M-C, Penson P, Mikhailidis DP, Toth PP, Jones SR, et al. Effects of morning vs evening statin administration on lipid profile: a systematic review and meta-analysis. J Clin Lipidol 2017;11:972-85 s.
• [6] Plakogiannis R, Cohen H. Optimal low-density lipoprotein cholesterol lowering - morning versus evening statin administration. Ann Pharmacother 2007;41:106-10.
• [7] Kim S, Thiessen PA, Bolton EE, Chen J, Fu G, Gindulyte A, et al. PubChem substance and compound databases. Nucleic Acids Res 2016;44:D1202-13.
• [8] Schrödinger L. PyMOL: the PyMOL molecular graphics system. New York: Schrödinger, LLC, 2018.
• [9] Cao Y, Charisi A, Cheng L-C, Jiang T, Girke T. ChemmineR: a compound mining framework for R. Bioinformatics 2008;24:1733-4.
• [10] Bader RF. Bond paths are not chemical bonds. J Phys Chem A 2009;113:10391-6.
• [11] Holliday JD, Salim N, Whittle M, Willett P. Analysis and display of the size dependence of chemical similarity coefficients. J Chem Inf Comput Sci 2003;43:819-28.
• [12] Cao Y, Jiang T, Girke T. A maximum common substructure-based algorithm for searching and predicting drug-like compounds. Bioinformatics. Oxford: Oxford University Press, 2008.
• [13] Maggiora G, Vogt M, Stumpfe D, Bajorath J. Molecular similarity in medicinal chemistry. J Med Chem 2014;57:3186-204.
• [14] Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
• [15] Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The Effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
• [16] Carter NJ. Rosuvastatin. Am J Cardiovasc Drug 2010;10:383-400.

Uwagi

Opracowanie rekordu w ramach umowy 509/P-DUN/2018 ze środków MNiSW przeznaczonych na działalność upowszechniającą naukę (2019).